The cost effectiveness of zanamivir and oseltamivir for influenza treatment

Edward P Armstrong, Z. M. Khan, A. S. Perry, M. A. Hons, L. R. Perri

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

In this month's column, the authors evaluate the cost effectiveness of oseltamivir and zanamivir, compared with standard care, for the treatment of influenza. Using efficacy data from randomized, placebo-controlled clinical trials, a cost-effectiveness model was constructed. In an influenza-positive patient population, the cost per symptom free day was $16 for zanamivir-treated patients compared with $39 for oseltamivir-treated patients. Considering a hypothetical drug budget of $100,000, 919 additional patients could be treated with zanamivir than with oseltamivir. Treatment with zanamivir would result in a gain of 1,714 symptom-free days and 52 fewer influenza-related complications than if oseltamivir were used.

Original languageEnglish (US)
Pages (from-to)979-989
Number of pages11
JournalFormulary
Volume35
Issue number12
StatePublished - 2000

Fingerprint

Zanamivir
Oseltamivir
Human Influenza
Cost-Benefit Analysis
Budgets
Therapeutics
Standard of Care
Randomized Controlled Trials
Placebos
Costs and Cost Analysis
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Armstrong, E. P., Khan, Z. M., Perry, A. S., Hons, M. A., & Perri, L. R. (2000). The cost effectiveness of zanamivir and oseltamivir for influenza treatment. Formulary, 35(12), 979-989.

The cost effectiveness of zanamivir and oseltamivir for influenza treatment. / Armstrong, Edward P; Khan, Z. M.; Perry, A. S.; Hons, M. A.; Perri, L. R.

In: Formulary, Vol. 35, No. 12, 2000, p. 979-989.

Research output: Contribution to journalArticle

Armstrong, EP, Khan, ZM, Perry, AS, Hons, MA & Perri, LR 2000, 'The cost effectiveness of zanamivir and oseltamivir for influenza treatment', Formulary, vol. 35, no. 12, pp. 979-989.
Armstrong EP, Khan ZM, Perry AS, Hons MA, Perri LR. The cost effectiveness of zanamivir and oseltamivir for influenza treatment. Formulary. 2000;35(12):979-989.
Armstrong, Edward P ; Khan, Z. M. ; Perry, A. S. ; Hons, M. A. ; Perri, L. R. / The cost effectiveness of zanamivir and oseltamivir for influenza treatment. In: Formulary. 2000 ; Vol. 35, No. 12. pp. 979-989.
@article{721ce09b9bdb4fb1ab1db964102347e3,
title = "The cost effectiveness of zanamivir and oseltamivir for influenza treatment",
abstract = "In this month's column, the authors evaluate the cost effectiveness of oseltamivir and zanamivir, compared with standard care, for the treatment of influenza. Using efficacy data from randomized, placebo-controlled clinical trials, a cost-effectiveness model was constructed. In an influenza-positive patient population, the cost per symptom free day was $16 for zanamivir-treated patients compared with $39 for oseltamivir-treated patients. Considering a hypothetical drug budget of $100,000, 919 additional patients could be treated with zanamivir than with oseltamivir. Treatment with zanamivir would result in a gain of 1,714 symptom-free days and 52 fewer influenza-related complications than if oseltamivir were used.",
author = "Armstrong, {Edward P} and Khan, {Z. M.} and Perry, {A. S.} and Hons, {M. A.} and Perri, {L. R.}",
year = "2000",
language = "English (US)",
volume = "35",
pages = "979--989",
journal = "Formulary",
issn = "1082-801X",
publisher = "Advanstar Communications",
number = "12",

}

TY - JOUR

T1 - The cost effectiveness of zanamivir and oseltamivir for influenza treatment

AU - Armstrong, Edward P

AU - Khan, Z. M.

AU - Perry, A. S.

AU - Hons, M. A.

AU - Perri, L. R.

PY - 2000

Y1 - 2000

N2 - In this month's column, the authors evaluate the cost effectiveness of oseltamivir and zanamivir, compared with standard care, for the treatment of influenza. Using efficacy data from randomized, placebo-controlled clinical trials, a cost-effectiveness model was constructed. In an influenza-positive patient population, the cost per symptom free day was $16 for zanamivir-treated patients compared with $39 for oseltamivir-treated patients. Considering a hypothetical drug budget of $100,000, 919 additional patients could be treated with zanamivir than with oseltamivir. Treatment with zanamivir would result in a gain of 1,714 symptom-free days and 52 fewer influenza-related complications than if oseltamivir were used.

AB - In this month's column, the authors evaluate the cost effectiveness of oseltamivir and zanamivir, compared with standard care, for the treatment of influenza. Using efficacy data from randomized, placebo-controlled clinical trials, a cost-effectiveness model was constructed. In an influenza-positive patient population, the cost per symptom free day was $16 for zanamivir-treated patients compared with $39 for oseltamivir-treated patients. Considering a hypothetical drug budget of $100,000, 919 additional patients could be treated with zanamivir than with oseltamivir. Treatment with zanamivir would result in a gain of 1,714 symptom-free days and 52 fewer influenza-related complications than if oseltamivir were used.

UR - http://www.scopus.com/inward/record.url?scp=0033637919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033637919&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033637919

VL - 35

SP - 979

EP - 989

JO - Formulary

JF - Formulary

SN - 1082-801X

IS - 12

ER -